Notably, while initially demonstrated in patients with T2DM, recent landmark trials have shown that semaglutide also significantly reduces primary cardiovascular endpoint events (including cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) in obese patients without diabetes, substantially expanding their potential cardioprotective applications
Published: Oct 11, 2025 Written by Klarity Editorial Team Published: Oct 11, 2025 Losing insurance coverage for your GLP-1 medication can feel like hitting a wall
While the kinetic rate constants could not be accurately determined for GLP-1 QMP, GLP-1 QMP/LX (0.2 nM) showed an almost 600-fold higher binding affinity compared to GLP-1 WT (Fig
Double-blind controlled trial of lecithinized superoxide dismutase in patients with idiopathic interstitial pneumonia short term evaluation of safety and tolerability
10.1016/j.bbagen.2013.04.006 Biochim
Food Chem Toxicol (2022) 164:113008